Global Ophthalmic Drugs Market (2021 to 2029) - Featuring Abbott Healthcare, Allergan and Bayer Among Others - ResearchAndMarkets.com

·4 min read

DUBLIN, October 20, 2021--(BUSINESS WIRE)--The "Ophthalmic Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 To 2029" report has been added to ResearchAndMarkets.com's offering.

The prescription type studied for analyzing the overall ophthalmic drugs market are prescription drugs and over-the-counter drugs (OTC). On the basis of therapeutic areas, the global ophthalmic drugs market is segmented into glaucoma ophthalmic drugs, retinal disorders ophthalmic drugs, dry eye ophthalmic drugs and allergic conjunctivitis. Market size and forecast for each of these segments for the period 2019-2022 are provided in this study along with respective CAGRs for the forecast period 2021-2029.

Companies Mentioned

  • Abbott Healthcare

  • Allergan Plc

  • Johnson & Johnson

  • Bayer

  • Valeant Pharmaceuticals, Inc.

  • Akorn

  • Renegeron

  • Eyemed

  • Senju Pharmaceutical Co., Ltd

  • Pfizer, Inc.

  • Merck & Co.

  • Novartis AG

  • Glaxo Smith Kline

  • Eyegate Pharmaceuticals

  • LPath

  • Senten Pharmaceutical Co. Ltd

  • Cipla Pharmaceuticals

  • Sun Pharmaceutical Industries, Ltd.

  • Other Notable Players

Market size and forecast for these regional and country level markets are presented in this study for the period 2019-2029. Market growth rates for the forecast period 2021-2029 are also included in this report, considering 2020 as the base year.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global ophthalmic drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global ophthalmic drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in ophthalmic drugs market.

The ophthalmic drug industry can be classified into prescription ophthalmic drugs and over the counter (OTC) drugs. OTC drugs are widely adopted due to the large number of glaucoma patients and increasing number of geriatric patients globally, creating a significant demand in the OTC drugs market. However, various side effects associated with the uptake of OTC medications would hinder the market growth for the OTC market segment. Prescription ophthalmic drugs segment is anticipated to grow at highest CAGR during the forecast period. The prime factor that would determine the growth of prescription drugs segment include the increasing number of patients suffering from various new retinal disorders and complicated cases of glaucoma and cataract. Moreover, increasing rate of success for newly launched drugs which can only be bought by prescriptions would further assist the market growth. Ophthalmic steroids need prescription to be given to the patient, as these products are specifically designed to be applied in eyes. These products contain corticosteroids and are available as eye drops, gels, ointments and other forms of ocular applications. Some of FDA approved prescription ophthalmic drugs include Acular, Omidria, Betaxon, Zaditor, and Zymaxid.

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Market Segmentation

Chapter 4 Global Ophthalmic Drugs Market Dynamics

4.1 Market Driver Analysis

4.1.1 Global Rise in Geriatric Population Pushing Ophthalmology Drugs

4.1.2 Technology Advancement

4.1.3 Innovation Giving Rise To Ophthalmology Drugs Market

4.1.4 Global Increase In Prevelance of Eye Diseases

4.1.5 Global Increase in Healthcare Expenditure

4.2 Market Driver Analysis

4.2.1 Major Drugs Going Off Patent Is Affecting the Growth of Ophthalmology Market

4.2.2 Drying Pipelines Is A Concern For Major Players

4.3 Key Opportunities Prioritized

4.2.1 Increasing Awareness

4.2.2 Emerging Markets

Chapter 5 Industry Analysis

6.1 Global Ophthalmic Drugs Market Industry - PESTEL Analysis

Chapter 6 Global Ophthalmic Drugs Market, By Prescription Type, 2019-2029 (USD Mn)

Chapter 7 Global Ophthalmic Drugs Market, By Therapeutic Type, 2019-2029 (USD Mn)

Chapter 8 Global Ophthalmology Drugs Market, By Geography

Chapter 9 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/b2dv3

View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005920/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting